Subsequent systemic therapy for all randomized patients
| Nivolumab plus ipilimumab with chemotherapy (n=361) | Chemotherapy (n=358) | |
| Received subsequent systemic therapy, n (%) | 135 (37) | 174 (49) |
| Any immunotherapy | 26 (7) | 130* (36) |
| Anti-PD-1 | 15 (4) | 107 (30) |
| Nivolumab | 11 (3) | 72 (20) |
| Pembrolizumab | 4 (1) | 36 (10) |
| Anti-PD-L1 | 8 (2) | 24 (7) |
| Anti-CTLA-4 | 2 (1) | 2 (1) |
| Other immunotherapy | 5 (1) | 6 (2) |
| Targeted therapy | 26 (7) | 30 (8) |
| Chemotherapy | 126 (35) | 99 (28) |
| Platinum-doublet chemotherapy | 71 (20) | 22 (6) |
Percentages based on all randomized patients. Patients may have received more than one type of subsequent therapy. Subsequent therapy was defined as therapy that started on or after the first dosing date (randomization date if the patient was never treated).
*Includes one patient who was randomized to the chemotherapy arm but did not receive treatment.